Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. - Remon, J.; Besse, B.; Aix, S. Ponce; Callejo, A.; Al-Rabi, K.; Bernabe, R.; Greillier, L.; Majem, M.; Reguart, N.; Monnet, I.; Cousin, S.; Garrido, P.; et al. (Annals of Oncology, 2023)